[
  {
    "ts": null,
    "headline": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
    "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
    "url": "https://finnhub.io/api/news?id=7019bfc40bd1a78a2625543202f89e570dc23fc764419fff1cabc9f7bb95b378",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770730320,
      "headline": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
      "id": 139031857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
      "url": "https://finnhub.io/api/news?id=7019bfc40bd1a78a2625543202f89e570dc23fc764419fff1cabc9f7bb95b378"
    }
  },
  {
    "ts": null,
    "headline": "Where is Genmab A/S (GMAB) Headed According to Wall Street?",
    "summary": "Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in. Genmab A/S (NASDAQ:GMAB) announced on January 21 that the worldwide net trade sales of DARZALEX, including sales of the subcutaneous product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J, came up to $14.351 billion […]",
    "url": "https://finnhub.io/api/news?id=68ce4c513218321d63ec0a52427c70a2c277e6dfb2e7bc12bff5ff8d50de543a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770723711,
      "headline": "Where is Genmab A/S (GMAB) Headed According to Wall Street?",
      "id": 139028386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in. Genmab A/S (NASDAQ:GMAB) announced on January 21 that the worldwide net trade sales of DARZALEX, including sales of the subcutaneous product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J, came up to $14.351 billion […]",
      "url": "https://finnhub.io/api/news?id=68ce4c513218321d63ec0a52427c70a2c277e6dfb2e7bc12bff5ff8d50de543a"
    }
  },
  {
    "ts": null,
    "headline": "4 takeaways from the 2026 AF Symposium",
    "summary": "Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation treatments, including pulsed field ablation catheters.",
    "url": "https://finnhub.io/api/news?id=e3bcd33d57506be4bd093293ac58acff6274ad467a547dd8b0d2811c3636b17a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770720830,
      "headline": "4 takeaways from the 2026 AF Symposium",
      "id": 139033426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation treatments, including pulsed field ablation catheters.",
      "url": "https://finnhub.io/api/news?id=e3bcd33d57506be4bd093293ac58acff6274ad467a547dd8b0d2811c3636b17a"
    }
  },
  {
    "ts": null,
    "headline": "Becton, Dickinson and Company: A Q1 2026 Earnings And Post Spin-Off Examination",
    "summary": "Becton, Dickinson and Company: A Q1 2026 Earnings And Post Spin-Off Examination",
    "url": "https://finnhub.io/api/news?id=d1f7b3aff4efceb35e057ee920fde62c364f280d994739d721d4e395f4401aac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770711346,
      "headline": "Becton, Dickinson and Company: A Q1 2026 Earnings And Post Spin-Off Examination",
      "id": 139028876,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d1f7b3aff4efceb35e057ee920fde62c364f280d994739d721d4e395f4401aac"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "summary": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770702333,
      "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
      "id": 139028076,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Highlights Pipeline Breadth Across Cardiology, Oncology And Vision Care",
    "summary": "Johnson & Johnson (NYSE:JNJ) reports strong 12 month pilot-phase data for its OMNYPULSE platform in atrial fibrillation treatment. The company shares expanded safety data for its VARIPULSE platform, also focused on atrial fibrillation care. Johnson & Johnson launches new daily disposable multifocal toric contact lenses within its ACUVUE product line. New real world evidence highlights ERLEADA as a leading therapy option for metastatic castration sensitive prostate cancer. For a healthcare...",
    "url": "https://finnhub.io/api/news?id=7d5fe74dbe26f3d90dd8efdea661907657d5b9b7cf495f9b635aa4d4c6ce4ba6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770693189,
      "headline": "Johnson & Johnson Highlights Pipeline Breadth Across Cardiology, Oncology And Vision Care",
      "id": 139026148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) reports strong 12 month pilot-phase data for its OMNYPULSE platform in atrial fibrillation treatment. The company shares expanded safety data for its VARIPULSE platform, also focused on atrial fibrillation care. Johnson & Johnson launches new daily disposable multifocal toric contact lenses within its ACUVUE product line. New real world evidence highlights ERLEADA as a leading therapy option for metastatic castration sensitive prostate cancer. For a healthcare...",
      "url": "https://finnhub.io/api/news?id=7d5fe74dbe26f3d90dd8efdea661907657d5b9b7cf495f9b635aa4d4c6ce4ba6"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia",
    "summary": "Today, Johnson & Johnson announced the launch of two new contact lenses in Singapore – ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM – the first and only daily disposable multifocal toric contact lens for people with both astigmatism and presbyopia,[1] and ACUVUE® OASYS MAX 1-Day for ASTIGMATISM. Designed to address the evolving needs of astigmatic patients, both lenses provide exceptional comfort, clarity and stability,[+],[**],[2],[3] plus crisp, clear vision at all distances and in all l",
    "url": "https://finnhub.io/api/news?id=50cb38c54d8174242844a5c46ebab769e0834c48cd263a90e4a903e082095259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770683400,
      "headline": "Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia",
      "id": 138973912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Today, Johnson & Johnson announced the launch of two new contact lenses in Singapore – ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM – the first and only daily disposable multifocal toric contact lens for people with both astigmatism and presbyopia,[1] and ACUVUE® OASYS MAX 1-Day for ASTIGMATISM. Designed to address the evolving needs of astigmatic patients, both lenses provide exceptional comfort, clarity and stability,[+],[**],[2],[3] plus crisp, clear vision at all distances and in all l",
      "url": "https://finnhub.io/api/news?id=50cb38c54d8174242844a5c46ebab769e0834c48cd263a90e4a903e082095259"
    }
  }
]